Tuesday, February 18, 2020 2:03:22 PM
On January 13, 2018 (two years ago) NWBO informed shareholders of the ASM scheduled on January 21, 2018, 8 days later. Notice that the proxy vote was included as an attachment in the email to shareholders.
On January 11, 2019 (last year), NWBO informed shareholders of the ASM scheduled on February 2, 2019, 22 days later. Notice that in the notification email, the proxy vote details were included here too.
Now today, January 18, NWBO informed shareholders of the ASM scheduled on April 18, 2020, 90 days later. The proxy details were not included in the email.
Why is NWBO notifying us of an ASM 90 days in advance, relative to the last two ASMs?
Why isn't the proxy details included as they were in previous communications? Is there some event/info in the proxy that they don't want to communicate yet?
Does anyone know when ASCO 2020 is scheduled?
On January 11, 2019 (last year), NWBO informed shareholders of the ASM scheduled on February 2, 2019, 22 days later. Notice that in the notification email, the proxy vote details were included here too.
Now today, January 18, NWBO informed shareholders of the ASM scheduled on April 18, 2020, 90 days later. The proxy details were not included in the email.
Why is NWBO notifying us of an ASM 90 days in advance, relative to the last two ASMs?
Why isn't the proxy details included as they were in previous communications? Is there some event/info in the proxy that they don't want to communicate yet?
Does anyone know when ASCO 2020 is scheduled?
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

